Reid IR, et al. - Among osteopenic postmenopausal women (aged ≥65 years), researchers determined the anti-fracture effectiveness of zoledronate. For this prospective, randomized, placebo-controlled, double-blind trial, they recruited 2,000 women using electoral rolls. Participants were randomly allocated to receive 4 infusions of either zoledronate 5 mg or normal saline at 18-month intervals. For 6 years, each participant was followed. In 190 women in the placebo group (227 fractures) and in 122 women in the zoledronate group (131 fractures), fragility fractures (either vertebral or non-vertebral) occurred. According to findings, the decline in numbers of fracture across this cohort was broadly consistent. The absence of a relationship between numbers needed to treat and baseline risk of fracture challenges the necessity in older postmenopausal women for BMD measurement and exact risk assessment of fracture prior to beginning treatment